Hematology: Trials and tribulations in primary CNS lymphoma

Nature Reviews Clinical Oncology

Volumn 7, Issue 3, 2010, Pages 125-126

  Ansell, Stephen M ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT DURATION; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77749252626     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.9     Document Type: Short Survey

References (10)

1. Olson, J. E. et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95, 1504-1510 (2002).
2. Mead, G. M. et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89, 1359-1370 (2000).
3. Nelson, D. F. et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23, 9-17 (1992).
4. Batchelor, T. et al. Treatment of primary Cns lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21, 1044-1049 (2003).
5. Shah, G. D. et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 25, 4730-4735 (2007).
6. Abrey, L. E., DeAngelis, L. M. & Yahalom, J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16, 859-863 (1998).
7. Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M. & Abrey, L. E. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 24, 4570-4574 (2006).
8. Abrey, L. E. et al. intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151-4156 (2003).
9. Fisher, B. et al. secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J. Neurooncol. 74, 201-205 (2005).
10. Ferreri, A. J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374, 1512-1520 (2009).